[Chemotherapy of chronic myelogenous leukemia in blastic crisis--vindesine, cytosine arabinoside prednisolone combination therapy].
Twenty patients with chronic myelogenous leukemia in terminal transformation were treated with regimen incorporating vindesine, prednisolone and additional cytosine arabinoside. Of the 19 patients in blastic crisis, complete remission was achieved in 13 (68.4%). All four patients with lymphoid morphology, and nine of the eleven patients with myeloid morphology, achieved complete remission (81.8%); the four with monocytoid morphology did not. One patient in accelerated phase also attained complete remission. The present results indicate that the regimen incorporating vindesine-cytosine arabinoside-prednisolone should be treatment of choice in CML-BC with lymphoid morphology and myeloid morphology as well.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014751:Vindesine
D003561:Cytarabine; D014747:Vinblastine; D011239:Prednisolone; D014751:Vindesine